Macro Trials is a technology company.
Macro Trials has raised $6.0M across 1 funding round.
Macro Trials has raised $6.0M in total across 1 funding round.
Macro Trials has raised $6.0M in total across 1 funding round.
Macro Trials's investors include Cota Capital, General Catalyst, MBX Capital, Pear VC, Plug & Play Ventures, Anne Wojcicki, Jennifer Lum.
Macro Trials is a technology-driven precision research clinical platform focused on accelerating clinical trials in healthcare and life sciences. It provides a digitally powered infrastructure that partners with pharmaceutical companies, contract research organizations (CROs), physicians, and health systems to design, plan, and execute clinical trials for high-value therapeutics. The platform addresses critical challenges such as under-representation of diverse populations in trials by enabling equitable patient recruitment at the site of care, thus improving trial inclusivity and real-world evidence generation. Macro Trials serves pharmaceutical sponsors, CROs, clinicians, and patients by simplifying trial participation, improving enrollment and retention rates, and optimizing study outcomes through real-time data capture and workflow-native tools[1][3][5].
Founded in 2021 and based in Los Angeles, Macro Trials was incubated by INITIATE Studios, a venture studio specializing in healthcare, life sciences, and technology startups. The founders identified a pressing need to transform clinical trials by increasing research velocity and inclusivity while reducing costs and complexity. Early traction included securing $6 million in seed funding to develop its platform, expand infrastructure across geographies and therapeutic areas, and scale its study execution capabilities. The company’s launch marked a pivotal moment in addressing systemic issues in clinical research, such as the lack of diversity and real-world evidence in drug development[1][3][4].
Macro Trials rides the growing trend of digital transformation and decentralization in clinical research, which has gained momentum due to the COVID-19 pandemic and increasing demand for more inclusive, patient-centric trials. The timing is critical as pharmaceutical companies face pressure to accelerate drug development while ensuring therapies are effective across diverse populations. Macro’s platform leverages market forces favoring real-world evidence and data-driven decision-making, positioning it as a key enabler in the shift toward precision medicine and equitable healthcare. By integrating clinical trials into everyday care settings, Macro influences the broader ecosystem by lowering barriers for physician participation and patient access, thus fostering a more representative and efficient clinical research environment[1][3][6].
Looking ahead, Macro Trials is poised to expand its geographic reach and therapeutic area coverage while enhancing its data generation and study execution capabilities. Trends such as increased regulatory emphasis on diversity, the rise of decentralized trials, and the integration of real-world evidence will shape its trajectory. As the company scales, it may deepen its influence by setting new standards for inclusivity and efficiency in clinical research, potentially accelerating the delivery of life-saving therapies to broader patient populations. Macro’s continued innovation in digital infrastructure and clinical trial intelligence will likely solidify its role as a transformative force in the healthcare technology landscape[1][3][5].
Macro Trials has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $6.0M Seed | Cota Capital, General Catalyst, MBX Capital, Pear VC, Plug & Play Ventures, Anne Wojcicki, Jennifer Lum |